Yahoo rumors about 20 news vans around Celera HQ, and I don't think it is because of this news just out. Although the enws is BIG and certainly a sign of more to come, I think the assembly news is being dissemitated!
Celera Genomics to Provide First Academic Subscription to Vanderbilt University; First Subscriber to Use Web-Based Celera Discovery System
Business Wire - May 07, 2000 14:15
Jump to first matched term
ROCKVILLE, Md.--(BUSINESS WIRE)--May 7, 2000--Celera Genomics (NYSE:CRA), a PE Corporation business, announced today it signed an agreement with Vanderbilt University that provides a five-year, comprehensive subscription to certain Celera database products. Vanderbilt will become the first subscriber to access Celera's database information through its Celera Discovery System(TM) on the World Wide Web. Financial terms of the agreement were not disclosed. The annual subscription rates are dependent on the nature of the subscription, size of the institution, and the number of concurrent users.
"It is very fitting that our first academic database subscription is with a premier medical and research institution such as Vanderbilt," said J. Craig Venter, Ph.D., Celera's president and chief scientific officer. "We firmly believe that researchers everywhere should have access to our genomic database information. With our web-based science discovery system we have provided the mechanism to do so."
"Vanderbilt's basic science departments are routinely ranked in the top ten in the nation year after year. Through continuing investments like this acquisition of genomic data and tools, we think we can provide a foundation for even more rapid growth," said Joe B. Wyatt, Vanderbilt Chancellor.
Vanderbilt's database subscription gives its academic researchers access until 2005 to four databases developed by Celera. All four of Celera's databases include Celera proprietary information as well as publicly available data. First, the Celera Human Gene Index provides customers with the set of human genes derived from EST sequencing programs. Second, Celera's Human Genome Database is expected to provide the complete sequence of the human genome and the entire collection of human genes with links to associated biological and disease information. Third, the Drosophila Genome Database provides the complete sequence of the Drosophila melanogaster genome sequence generated by Celera's whole genome shotgun sequencing strategy. The Drosophila genome database is extensively annotated with gene, protein and biological information. Fourth, the Mouse Genome Database being generated by Celera should allow for comparative analysis with the human genome that may be especially significant for the identification of genes and gene regulatory regions of importance to understanding human biology. Access to the databases also provides Vanderbilt researchers with associated comprehensive bioinformatics systems and tools for viewing, browsing, and analyzing genomic information.
"We believe that Vanderbilt's subscription to Celera's databases is validation of the importance of genomic information. We hope access to our data will enable Vanderbilt's renowned researchers to advance their work in genomics," said Tony L. White, PE Corporation chairman, president and chief executive officer.
Celera Discovery System
The CeleraScience(TM) portal provides genomic and proteomic data as well as medical news. The portal also features educational information and access to the Celera Discovery System. The CeleraScience portal is designed for users to access a broad array of public news and special features by a staff of independent medical and science writers. Through the Celera Discovery System, subscription-based customers can access Celera's expanding databases and analysis tools. The flexible architecture utilizes one platform to deliver incremental levels of value depending on the subscription level chosen by the customer. This is intended to allow Celera to serve a variety of users including academic, biotechnology, pharmaceutical, and public.
Essential features of the Celera's Discovery System subscriptions include:
*T
-- Access to Celera's unique database content including
annotation, extensive computational resources, and software
tools for analysis
-- A single platform for viewing and analyzing integrated
database resources
-- Freedom for academic subscribers to publish their discoveries
and develop intellectual property on their discoveries without
royalties or "reach through" rights to Celera
-- Secure web-based access to Celera's databases
-- Value added annotation
-- Training and subscriber support *T
Vanderbilt University is a selective, comprehensive teaching and research university. Ten schools offer both an outstanding undergraduate program and a full range of graduate and professional programs. With a prestigious faculty of more than 1,700 full-time and 300 part-time members, Vanderbilt attracts a diverse student body of approximately 5,900 undergraduates and 4,300 graduate and professional students from all 50 states and over 90 foreign countries.
PE Corporation currently comprises two operating groups. Celera Genomics Group, headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. PE Biosystems Group, headquartered in Foster City, CA and with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software, and contract related services to the life science industry and research community. Information about the company, including consolidated financial statements of PE Corporation, is available on the World Wide Web at pecorporation.com or by phoning (800) 762-6923.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "anticipate," "should," "intend," "planned," "estimated," and "potential," among others. These forward-looking statements are based on PE Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses include but are not limited to (1) operating losses to date; (2) a unique and developing business plan; (3) dependence on the timely completion of the sequencing and assembly of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the PE Biosystems group; (9) potential product liability claims; (10) liabilities related to use of hazardous materials; (11) lengthy sales cycle; (12) dependence on the unique expertise of its scientific and management staff; (13) uncertainty of patent, copyright and intellectual property protection; (14) dependence on computer hardware, software, and internet applications; (15) access to biological materials; (16) legal, ethical and social issues affecting demand for products; (17) disruptions caused by rapid growth of the business; (18) government regulation of its products and services; (19) risks of future acquisitions; and (20) other factors that might be described from time to time in PE Corporation's filings with the Securities and Exchange Commission.
Copyright (c) 2000. PE Corporation. All Rights Reserved.
Celera, Celera Genomics, Celera Discovery System, CeleraScience, and PE Biosystems are trademarks of PE Corporation.
marketwatch.newsalert.com |
